Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.